NEW YORK, USA and MELBOURNE, Australia, 30 July, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies, is pleased to announce that it has completed participant dosing in the IHL-42X Bioavailability/Bioequivalence (BA/BE) clinical trial. IHL-42X comprises two drugs, dronabinol…
Early-Stage GLP-1 Win in Obesity; An Argument for BMI’s Value; Insulin Supply Issues
Participants in a phase I trial lost a placebo-adjusted 6.1% of their body weight after 4 weeks of treatment with the investigational oral GLP-1 receptor
July 24, 2024